Tech Company Financing Transactions
Diagonal Therapeutics Funding Round
Diagonal Therapeutics closed a $128 million investment round on 4/4/2024. Investors included Atlas Venture, BVF Partners and Frazier Life Sciences.
Transaction Overview
Company Name
Announced On
4/4/2024
Transaction Type
Venture Equity
Amount
$128,000,000
Round
Undisclosed
Investors
Atlas Venture (Lead Investor)
BVF Partners (Lead Investor)
Proceeds Purpose
The company intends to use the funds for further advancement of its proprietary platform and pipeline of novel therapeutics to value-creating milestones, including its lead program for the treatment of hereditary hemorrhagic telangiectasia (HHT), a severely debilitating bleeding disorder with limited therapeutic options, through clinical proof-of-concept.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
300 Technology Square, 8th Floor
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Undisclosed
Website
Email Address
Overview
At Diagonal Therapeutics, we have assembled a team of scientific and business leaders with extensive experience in building companies and developing innovative antibody therapies.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Alex Lugovskoy
Chief Scientific Officer
Patrick Andre
Vice President
Melissa Geddie
VP - Bus. Development
Sandra Teixeiraq
VP - Finance
Eric Duhaime
Browse more venture capital transactions:
Prev: 4/4/2024: Adon Health venture capital transaction
Next: 4/4/2024: Biolinq venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. All VC database entries on this site are derived from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs